Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02969382 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate the Efficacy and Safety of SEP-363856 in Acutely Psychotic Adults With Schizophrenia
A Phase 2 study, sponsored by Otsuka Pharmaceutical Development & Commercialization.
- Completed
- Registry status
- Phase 2
- Development phase
- 245
- Enrollment target
NCT02969382 is a Phase 2 study that has completed, run by Otsuka Pharmaceutical Development & Commercialization. The registered enrollment target is 245 participants.
The verdict
NCT02969382, a Phase 2 study, has completed, sponsored by Otsuka Pharmaceutical Development & Commercialization.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 245 participants
- Enrollment target
Study Summary
A study to evaluate the efficacy and safety of an experimental drug (SEP-363856) in acutely psychotic adults with schizophrenia
Interventions
- DRUG SEP-363856
- DRUG Placebo - Cap
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 245 participants |
| Start Date | 2016-12-05 |
| Est. Completion | 2018-07-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02969382
The ClinicalTrials.gov registry entry for NCT02969382 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 245 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Otsuka Pharmaceutical Development & Commercialization, which has 221 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which SEP-363856 is the first listed.
NCT02969382 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02969382 about?
NCT02969382 is a clinical study titled "A Study to Evaluate the Efficacy and Safety of SEP-363856 in Acutely Psychotic Adults With Schizophrenia". A study to evaluate the efficacy and safety of an experimental drug (SEP-363856) in acutely psychotic adults with schizophrenia
What is the current status of trial NCT02969382?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 245 participants. The study started on 2016-12-05. Estimated completion is 2018-07-31.
What interventions are being tested in trial NCT02969382?
The interventions under investigation include: SEP-363856 (DRUG), Placebo - Cap (DRUG).
Who is sponsoring clinical trial NCT02969382?
This trial is sponsored by Otsuka Pharmaceutical Development & Commercialization, which has 221 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.